Detalles de la búsqueda
1.
Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.
J Natl Cancer Inst
; 92(14): 1143-50, 2000 Jul 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-10904087
2.
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party.
J Natl Cancer Inst
; 91(10): 839-46, 1999 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-10340903
3.
Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators.
J Clin Oncol
; 13(1): 33-41, 1995 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-7799039
4.
Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer.
J Clin Oncol
; 15(7): 2526-35, 1997 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-9215821
5.
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials.
J Clin Oncol
; 19(6): 1688-97, 2001 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11250998
6.
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
J Clin Oncol
; 15(5): 1844-52, 1997 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-9164194
7.
Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: preliminary results of a double-blind randomized study of the EORTC Breast Cancer Cooperative Group.
J Steroid Biochem Mol Biol
; 37(6): 1109-13, 1990 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-2285584
8.
Sample size estimation in phase III cancer clinical trials.
Eur J Surg Oncol
; 25(3): 244-50, 1999 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-10336801
9.
Analysing longitudinal continuous quality of life data with dropout.
Stat Methods Med Res
; 11(1): 5-23, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11923994
10.
Currently active protocols in the EORTC Breast Cancer Cooperative Group.
Recent Results Cancer Res
; 91: 263-7, 1984.
Artículo
en Inglés
| MEDLINE | ID: mdl-6374800
11.
Estrogen receptors and distribution of prognostic factors in primary breast cancer.
Recent Results Cancer Res
; 91: 141-4, 1984.
Artículo
en Inglés
| MEDLINE | ID: mdl-6729209
12.
Estrogen receptor variations in neoplastic tissue during the course of disease in patients with recurrent breast cancer.
Recent Results Cancer Res
; 91: 181-5, 1984.
Artículo
en Inglés
| MEDLINE | ID: mdl-6729214
13.
A bayesian approach to the design of phase II clinical trials.
Biometrics
; 44(3): 823-36, 1988 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-3203131
14.
Design of phase II clinical trials in cancer using decision theory.
Cancer Treat Rep
; 64(2-3): 519-24, 1980.
Artículo
en Inglés
| MEDLINE | ID: mdl-7407793
15.
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Eur Urol
; 33(2): 134-43, 1998.
Artículo
en Inglés
| MEDLINE | ID: mdl-9519354
16.
Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer.
Cancer
; 46(12 Suppl): 2889-95, 1980 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-7448734
17.
Identifying the types of missingness in quality of life data from clinical trials.
Stat Med
; 17(5-7): 739-56, 1998.
Artículo
en Inglés
| MEDLINE | ID: mdl-9549820
18.
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Prostate
; 48(1): 29-39, 2001 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11391684
19.
Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer.
Cancer
; 39(5): 1971-7, 1977 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-870163
20.
Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial.
J Urol
; 162(5): 1658-64; discussion 1664-5, 1999 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-10524892